Sign in

CIK 0001842295

  • Non-accelerated filer
  • Emerging growth company

Maze Therapeutics, Inc.

Sign in to watch
Ticker
MAZE
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 650-850-5070
Business address
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$5,785,701
in 13 filings, $4.6M under 10b5-1 plans

Net −$5,785,701. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2026-06-08 Lim Jonathan E Director Grant or award · Stock Option (Right to Buy) +18,000 18,000
2025-09-22 Lim Jonathan E Director Grant or award · Stock Option (Right to Buy) +18,000 18,000
2025-02-03 Lim Jonathan E Director Conversion +37,724 37,724
2025-02-03 Lim Jonathan E Director Conversion +270,232 307,956
2025-02-03 Lim Jonathan E Director Conversion · Series A Preferred Stock −363,703 0
2025-02-03 Lim Jonathan E Director Conversion · Series B Preferred Stock −2,231,381 0
2024-12-09 Lim Jonathan E Director Grant or award · Stock Option (Right to Buy) +5,704 5,704
2024-12-09 Lim Jonathan E Director Returned to the company · Stock Option (Right to Buy) −5,704 0
2024-12-09 Lim Jonathan E Director Grant or award · Stock Option (Right to Buy) +9,086 9,086

Page 1 of 1 · 9 trades